Cognition Therapeutics (CGTX) Operating Leases (2022 - 2026)
Cognition Therapeutics (CGTX) posted quarterly Operating Leases of $176000.0 for Q1 2026, down 37.14% year-over-year from $280000.0 in Q1 2025, and down 9.74% quarter-over-quarter from $195000.0 in Q4 2025.
Cognition Therapeutics (CGTX) Operating Leases (2022 - 2026) Analysis & Trends
Cognition Therapeutics (CGTX) has reported Operating Leases for 5 consecutive years, with $176000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases fell 37.14% year-over-year to $176000.0; the TTM figure through Mar 2026 stood at $176000.0 (down 37.14% YoY), while the FY2025 annual figure was $195000.0, down 42.98% from the prior year.
- Operating Leases slipped to $176000.0 in Q1 2026 per CGTX's latest filing, from $195000.0 in the prior quarter.
- Across five years, Operating Leases topped out at $695000.0 in Q4 2022 and bottomed at $176000.0 in Q1 2026.
- Historically, Operating Leases has averaged $426235.3 across 5 years, with a median of $440000.0 in 2024.
- Annual changes were most pronounced in 2023 — Operating Leases surged 50.5% — and 2025, when it slumped 47.95%.
- Cognition Therapeutics' Operating Leases stood at $695000.0 in 2022, then dropped by 25.18% to $520000.0 in 2023, then tumbled by 34.23% to $342000.0 in 2024, then plunged by 42.98% to $195000.0 in 2025, then fell by 9.74% to $176000.0 in 2026.
- Business Quant data shows CGTX's Operating Leases at $176000.0 in Q1 2026, $195000.0 in Q4 2025, and $212000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cognition Therapeutics | 90.18 Mn | 90.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 422,000.00 |
| Mar 31, 2026 | 176,000.00 |
| Dec 31, 2025 | 195,000.00 |
| Sep 30, 2025 | 212,000.00 |
| Jun 30, 2025 | 229,000.00 |
| Mar 31, 2025 | 280,000.00 |
| Dec 31, 2024 | 342,000.00 |
| Sep 30, 2024 | 392,000.00 |
| Jun 30, 2024 | 440,000.00 |
| Mar 31, 2024 | 488,000.00 |
| Dec 31, 2023 | 520,000.00 |
| Sep 30, 2023 | 565,000.00 |
| Jun 30, 2023 | 608,000.00 |
| Mar 31, 2023 | 651,000.00 |
| Dec 31, 2022 | 695,000.00 |
| Sep 30, 2022 | 603,000.00 |
| Jun 30, 2022 | 404,000.00 |
| Mar 31, 2022 | 446,000.00 |